Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MATTSON, R. H.
Right arrow Articles by HANAHAN, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MATTSON, R. H.
Right arrow Articles by HANAHAN, E.
NEUROLOGY 1976;26:1014
© 1976 American Academy of Neurology

Eterobarb therapy in epilepsy

RICHARD H. MATTSON, M.D., PETER D. WILLIAMSON, M.D. and ELENE HANAHAN

From the Epilepsy Center, Veterans Administration Hospital, West Haven; Yale-New Haven Hospital; and the Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

A group of 27 patients with various types of epilepsy were selected for a 6-month double-blind crossover study to compare the anticonvulsant effect and toxicity of eterobarb and phenobarbital. No statistically significant differences in seizure frequency were found among the 21 patients who completed the 6-month trial, but three others, in whom status epilepticus developed during the crossover from eterobarb to phenobarbital, had to be removed from the trial. The study provided some indication that when eterobarb and phenobarbital were used in high dosage with corresponding high serum barbiturate levels (over 30 µg per milliliter), eterobarb had a superior therapeutic effect. Side effects from both drugs included tiredness, sleepiness, nystagmus, and infrequently ataxia, but serious systemic toxicity did not occur. This study showed that eterobarb is a safe and potent anticonvulsant comparable in efficacy to phenobarbital, and the superior results obtained in some patients with eterobarb therapy indicate that it is an effective alternative anticonvulsant.

Dr. Mattson's address is Epilepsy Center, Veterans Administration Hospital, West Haven, CT 06516.

This paper was presented in part at the twenty-seventh annual meeting of the American Academy of Neurology, Bal Harbour, Florida, May 1-4, 1975.

This study was supported in part by the Veterans Administration, NIH grant (No. USPHS 5P01NS06208) and the Kendall Company, Lexington, Massachusetts.

Received for publication December 1, 1975.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.